University of Groningen
Complement activation in chronic kidney disease and dialysis
Gaya da Costa, Mariana
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Gaya da Costa, M. (2019). Complement activation in chronic kidney disease and dialysis. Rijksuniversiteit
Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Stellingen behorende bij het proefschrift
‘Complement activation in chronic kidney disease
and dialysis’
Mariana Gaya da Costa, Rijksuniversiteit Groningen
1. Choosing the appropriate target to inhibit the complement system will determine the success of future complement-targeted therapies in kidney disease. (this thesis)
2. Intradialytic complement activation is a determinant of cardiovascular risk in hemodialysis patients. (this thesis)
3. Targeting complement activation in hemodialysis patients has the potential to prevent the thrombo-inflammation caused by hemodialysis. (this thesis)
4. Hemodialysis patients might benefit from complement inhibition only during the hemodialysis session, whereas peritoneal dialysis patients might need continuous complement inhibition. (this thesis)
5. In peritoneal dialysis, systemic and local complement activation are independent processes. (this thesis)
6. Considering the complement-activating ability of intravenous iron sucrose, other iron formulations should be preferred for the treatment of anemia. (this thesis)
7. The effectiveness of complement therapeutics in diseases should be assessed separately in female and older patients through additional clinical trials. (this thesis)
8. Only those who will risk going too far can possibly find out how far one can go. (T.S.Elliot) 9. For the things we have to learn before we can do them, we learn by doing them.
(Aristotle)
10. It is literally true that you can succeed best and quickest by helping others to succeed. (Napolean Hill)
